Correction: Tumor Necrosis Factor-Like Weak Inducer of Apoptosis or Fn14 Deficiency Reduce Elastase Perfusion-Induced Aortic Abdominal Aneurysm in Mice [J Am Heart Assoc., 3, (2014) e000723] DOI: 10.1161/JAHA.113.000723;Tumor necrosis factor-like weak inducer of apoptosis or Fn14 deficiency reduce elastase perfusion-induced aortic abdominal aneurysm in mice

Journal of the American Heart Association

Volumn 3, Issue 4, 2014, Pages

  Tarín, Carlos ^a   Ferńandez Laso, Valvanera ^a   Sastre, Cristina ^a   Madrigal Matute, Julio ^a   Gómez, Mónica ^b   Zaragoza, Carlos ^c   Egido, Jesús ^a   Burkly, Linda C ^d   Martín Ventura, Jose L ^a   Blanco Colio, Luis M ^a  

^a Instituto de Investigación Sanitaria Fundación Jiménez Díaz   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d BIOGEN   (United States)

Author keywords

Aneurysm; Fn14; Inflammation; MMP activity; TWEAK

Indexed keywords

ELASTASE; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; CCL2 PROTEIN, MOUSE; CCL5 PROTEIN, MOUSE; GELATINASE B; MMP9 PROTEIN, MOUSE; MONOCYTE CHEMOTACTIC PROTEIN 1; PANCREATIC ELASTASE; RANTES; TNFSF12 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

ABDOMINAL AORTA ANEURYSM; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CD3+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; FLUORESCENCE MOLECULAR TOMOGRAPHY; IMMUNOHISTOCHEMISTRY; MEMBRANE DAMAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TOMOGRAPHY; VASCULAR SMOOTH MUSCLE; ANIMAL; APOPTOSIS; CHEMICALLY INDUCED; CYTOLOGY; DISEASE MODEL; GENETICS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; NEUTROPHIL; SMOOTH MUSCLE CELL; T LYMPHOCYTE;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; APOPTOSIS; CHEMOKINE CCL2; CHEMOKINE CCL5; DISEASE MODELS, ANIMAL; INFLAMMATION; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEUTROPHILS; PANCREATIC ELASTASE; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES; TUMOR NECROSIS FACTORS;

EID: 84922679209     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.113.000723     Document Type: Erratum

References (37)

1. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006;26:2605-2613.
2. Michel JB, Thaunat O, Houard X, Meilhac O, Caligiuri G, Nicoletti A. Topological determinants and consequences of adventitial responses to arterial wall injury. Arterioscler Thromb Vasc Biol. 2007;27:1259-1268.
3. Sakalihasan N, Limet R, Dewafe OD. Abdominal aortic aneurysm. Lancet. 2005;365:1577-1589.
4. Powell JT, Brady AR. Detection, management, and prospects for the medical treatment of small abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004;24:241-245.
5. Pearce WH, Koch AE. Cellular components and features of immune response in abdominal aortic aneurysms. Ann N Y Acad Sci. 1996;800:175-185.
6. Newman KM, Jean-Claude J, Li H, Ramey WG, Tilson M. Cytokines that activate proteolysis are increased in abdominal aortic aneurysms. Circulation. 1994;90: II224-II227.
7. Koch AE, Haines GK, Rizzo RJ, Radosevich JA, Pope RM, Robinson PG, Pearce WH. Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response. Am J Pathol. 1990;137:1199-1213.
8. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995;15:1145-1151.
9. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7:411-425.
10. Munoz-Garcia B, Martin-Ventura JL, Martínez E, Sánchez S, Hernández G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke. 2006;37:2044-2053.
11. Blanco-Colio LM, Martín-Ventura JL, Munoz-Garcia B, Orbe J, Páramo JA, Michel J-B, Ortiz A, Meilhac O, Egido J. Identification of soluble tumor necrosis factorlike weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:916-922.
12. Martín-Ventura JL, Lindholt JS, Moreno JA, Vega de Céniga M, Meilhac O, Michel JB, Egido J, Blanco-Colio LM. Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis. 2011;214:486-489.
13. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K. Proinflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2002;299:488-493.
14. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem. 1999;274:8455-8459.
15. Munoz-Garcia B, Madrigal-Matute J, Moreno JA, Martín-Ventura JL, Lopez-Franco O, Sastre C, Ortega L, Burkly LC, Egido J, Blanco-Colio LM. TWEAKFn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc Res. 2011;89:225-233.
16. Munoz-Garcia B, Moreno JA, Lopez-Franco O, Sanz AB, Martin-Ventura JL, Blanco J, Jakubowski A, Burkly LC, Ortiz A, Egido J, Blanco-Colio LM. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 2009;29:2061-2068.
17. Caligiuri G, Rossignol P, Julia P, Groyer E, Mouradian D, Urbain D, Misra N, Ollivier V, Sapoval M, Boutouyrie P, Kaveri SV, Nicoletti A, Lafont A. Reduced immunoregulatory CD31+ T cells in patients with atherosclerotic abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2006;26:618-623.
18. Girgenrath M, Weng S, Kostek CA, Browning B, Wang M, Brown SA, Winkles JA, Michaelson JS, Allaire N, Schneider P, Scott ML, Hsu YM, Yagita H, Flavell RA, Miller JB, Burkly LC, Zheng TS. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J. 2006;25:5826-5839.
19. Dohi T, Borodovsky A, Wu P, Shearstone JR, Kawashima R, Runkel L, Rajman L, Dong X, Scott ML, Michaelson JS, Jakubowski A, Burkly LC. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology. 2009;136:912-923.
20. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, Ennis TL, Shapiro SD, Senior RM, Thompson RW. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-1649.
21. Sun J, Sukhova GK, Yang M, Wolters PJ, MacFarlane LA, Libby P, Sun C, Zhang Y, Liu J, Ennis TL, Knispel R, Xiong W, Thompson RW, Baxter BT, Shi GP. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest. 2007;117:3359-3368.
22. Choke E, Thompson MM, Dawson J, Wilson WR, Sayed S, Loftus IM, Cockerill GW. Abdominal aortic aneurysm rupture is associated with increased medial neovascularization and overexpression of proangiogenic cytokines. Arterioscler Thromb Vasc Biol. 2006;26:2077-2082.
23. Houard X, Touat Z, Ollivier V, Louedec L, Philippe M, Sebbag U, Meilhac O, Rossignol P, Michel JB. Mediators of neutrophil recruitment in human abdominal aortic aneurysm. Cardiovasc Res. 2009;82:532-541.
24. Middleton RK, Bown MJ, Lloyd GM, Jones JL, London NJ, Sayers RD. Characterisation of interleukin-8 and monocyte chemoattractant protein-1 expression within the abdominal aortic aneurysm and their association with mural inflammation. Eur J Vasc Endovasc Surg. 2009;37:46-55.
25. López-Candales A, Holmes DR, Liao S, Scott MJ, Wickline SA, Thompson RW. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol. 1997;150:993-1007.
26. Fontaine V, Touat Z, El Mtairag M, Vranckx R, Louedec L, Houard X, Andreassian B, Sebbag U, Palombi T, Jacob MP, Meilhac O, Michel JB. Role of leukocyte elastase in preventing cellular re-colonization of the mural thrombus. Am J Pathol. 2004;164:2077-2087.
27. Satta J, Laurila A, Pääkkö P, Haukipuro K, Sormunen R, Parkkila S, Juvonen T. Chronic inflammation and elastin degradation in abdominal aortic aneurysm disease: an immunohistochemical and electron microscopic study. Eur J Vasc Endovasc Surg. 1998;15:313-319.
28. Burkly LC, Dohi T. The TWEAK/Fn14 pathway in tissue remodeling: for better or for worse. Adv Exp Med Biol. 2011;691:305-322.
29. Haile WB, Echeverry R, Wu J, Yepes M. The interaction between tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factorinducible 14 promotes the recruitment of neutrophils into the ischemic brain. J Cereb Blood Flow Metab. 2010;30:1147-1156.
30. Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y, Kim DI, Park YB, Kwon BS, Park JE, Lee WH. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J. 2004;68:396-399.
31. Moehle CW, Bhamidipati CM, Alexander MR, Mehta GS, Irvine JN, Salmon M, Upchurch GR Jr, Kron IL, Owens GK, Ailawadi G. Bone marrow-derived MCP1 required for experimental aortic aneurysm formation and smooth muscle phenotypic modulation. J Thorac Cardiovasc Surg. 2011;142:1567-1574.
32. Iida Y, Xu B, Xuan H, Glover KJ, Tanaka H, Hu X, Fujimura N, Wang W, Schultz JR, Turner CR, Dalman RL. Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression. Arterioscler Thromb Vasc Biol. 2013;33:718-726.
33. Tedesco MM, Terashima M, Blankenberg FG, Levashova Z, Spin JM, Backer MV, Backer JM, Sho M, Sho E, McConnell MV, Dalman RL. Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression. Arterioscler Thromb Vasc Biol. 2009;29:1452-1457.
34. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, Su L, Tarilonte L, Crowell T, Rajman L, Runkel L, Scott M, Atkins GJ, Findlay DM, Zheng TS, Hess H. TWEAK is a novel arthritogenic mediator. J Immunol. 2006;177:2610-2620.
35. Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, Gorbatov R, Sukhova GK, Gerhardt LM, Smyth D, Zavitz CC, Shikatani EA, Parsons M, van Rooijen N, Lin HY, Husain M, Libby P, Nahrendorf M, Weissleder R, Swirski FK. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19:1166-1172.
36. Li H, Mittal A, Paul PK, Kumar M, Srivastava DS, Tyagi SC, Kumar A. Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy. J Biol Chem. 2009;284:4439-4450.
37. Dohi T, Burkly LC. The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases. J Leukoc Biol. 2012;92:265-279.